

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. BSA 04-02	SERIAL NO. Unassigned
	APPLICANT Haitao Wu et al.	CONFIRMATION NO. Unassigned
	FILING DATE Concurrently	GROUP Unassigned

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
		2003/0032799 A1	2-13-03	Miura et al.	_____	_____	
		2003/0083494 A1	5-1-03	Miura et al.	_____	_____	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
MB		4,783,529	11-8-88	Lavallee et al.	_____	_____	
MB		4,959,356	9-25-90	Miura et al.	_____	_____	
		5,149,801	9-22-92	Kahl et al.	_____	_____	
		5,162,231	11-10-92	Cole et al.	_____	_____	
		5,268,371	12-7-93	Mauclair et al.	_____	_____	
		5,312,896	5-17-94	Bhardwaj et al.	_____	_____	
		5,563,132	10-8-96	Bodaness	_____	_____	
		5,654,423	8-5-97	Kahl et al.	_____	_____	
		5,674,467	10-7-97	Maier et al.	_____	_____	
		5,877,165	3-2-99	Miura et al.	_____	_____	
		5,955,586	9-21-99	Sessler et al.	_____	_____	
		6,010,805	1-4-00	Scanlon, Jr. et al.	_____	_____	
		6,066,628	5-23-00	Stojiljkovic et al.	_____	_____	
		6,566,517	5-20-03	Miura et al.	_____	_____	

EXAMINER

DATE CONSIDERED

11/9/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. BSA 04-02	SERIAL NO. Unassigned
	APPLICANT Haitao Wu et al.	CONFIRMATION NO. Unassigned
	FILING DATE Concurrently	GROUP Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>ME</i>		WO 01/85736 A1	11-15-01	PCT	 	 		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>ME</i>	1.	Morris et al., "Porphyrin-mediated boron neutron capture therapy: evaluation of the reactions of skin and central nervous system," <i>Int. J. Radiat. Biol.</i> , 79(3): 149-158 (2003).
	2.	Vincente, et al., "Synthesis, dark toxicity, and induction of <i>in vitro</i> DNA photodamage by a tetra (4- <i>nido</i> -carboranylphenyl)prophyrin," <i>J. Photochem. Photobiol. B. Biology</i> , 68(2-3): 123-132 (2002).
	3.	Maderna et al., "Synthesis of a porphyrin-labelled carboranyl phosphate diester: a potential new drug for boron neutron capture therapy of cancer," <i>Chem. Commun.</i> , 16: 1784-1785 (2002).
	4.	Miura et al., "Boron Neutron Capture of a Murine Mammary Carcinoma using a Lipophilic Carboranyltetraphenylporphyrin," <i>Radiat. Res.</i> , 155(4): 603-610 (2001).
	5.	Miura et al., "Evaluation of carborane-containing porphyrins as tumor targeting agents for boron neutron capture therapy," <i>Br. J. Radiol.</i> , 71(847): 773-781 (1998).
<i>↓</i>	6.	Miura et al., "Synthesis of a Nickel Tetracarboranylphenylporphyrin for Boron Neutro-Capture Therapy: Biodistribution and Toxicity in Tumor-Bearing Mice," <i>Int. J. Cancer</i> , 68(1): 114-119 (1996).

EXAMINER

DATE CONSIDERED

11/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. BSA 04-02	SERIAL NO. Unassigned
	APPLICANT Haitao Wu et al.	CONFIRMATION NO. Unassigned
	FILING DATE Concurrently	GROUP Unassigned

ME	7.	Kahl et al., "A Carboranyl Porphyrin for Boron Neutron Capture Therapy of Brain Tumors," <i>Basic Life Sci.</i> , 50: 193-203 (1989).
	8.	Miura et al., "Biodistribution of copper carboranyltetraphenylporphyrins in rodents bearing an isogenic or human neoplasm," <i>J. NeuroOncol.</i> , 5: 111-117 (2001).
	9.	Berlin et al., "Are Porphyrin Mixtures Favorable Photodynamic Anticancer Drugs? A Model Study with Combinatorial Libraries of Tetraphenylporphyrins," <i>Combinatorial Chemistry</i> , 61(2): 107-118 (1998).
	10.	Miller et al., "In Vivo Animal Studies with Gadolinium (III) Texaphyrin As a Radiation Enhancer," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> , 45(4): 981-989 (1999).
	11.	Bhyrappa et al., "Octabromotetraphenylporphyrin and Its Metal Derivatives: Electronic Structure and Electrochemical Properties," <i>Inorg. Chem.</i> , 30: 239-245 (1991).
	12.	Birnbaum et al., " ¹⁹ F NMR Spectra and Structures of Halogenated Porphyrins," <i>Inorg. Chem.</i> , 34(14): 3625-3632 (1995).
	13.	Fairchild et al., "Current Status of ¹⁰ B-Neutron Capture Therapy: Enhancement of Tumor Dose Via Beam Filtration and Dose Rate, and the Effects of These Parameters on Minimum Boron Content: a Theoretical Evaluation," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> , 11(4): 831-840 (1985).
✓	14.	Woller et al., "2, 3, 7, 8, 12, 13, 17, 18-Octafluoro-5, 10, 15, 20-tetraarylporphyrins and Their Zinc Complexes: First Spectroscopic, Electrochemical, and Structural Characterization of a Perfluorinated Tetraarylmetalloporphyrin," <i>J. Org. Chem.</i> , 62(6): 1588-1593 (1997).

EXAMINER

DATE CONSIDERED

11/9/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. BSA 04-02	SERIAL NO. Unassigned
	APPLICANT Haitao Wu et al.	CONFIRMATION NO. Unassigned
	FILING DATE Concurrently	GROUP Unassigned

15.		Woller et al., "A Straightforward Synthesis of 3,4-Difluoropyrrole," <i>J. Org. Chem.</i> , 63(16): 5706-5707 (1998).
16.		Ozette et al., "New Metalloporphyrins with Extremely Altered Redox Properties: Synthesis, Structure, and Facile Reduction to Air-Stable n-Anion Radicals of Zinc and Nickel β -Heptanitroporphyrins," <i>J. Am. Chem. Soc.</i> , 119(27): 6442-6443 (1997).
17.		Chanana et al., "Boron Neutron Capture Therapy for Glioblastoma Multiforme: Interim Results from the Phase I/II Dose-Escalation Studies," <i>Neurosurgery</i> , 44(6): 1182-1193 (1999).
18.		Vincente et al., "Syntheses of carbon - carbon linked carboranylated porphyrins for boron neutron capture therapy of cancer." <i>Tetrahedron Letters</i> , 41: 7623-7627 (2000).
19.		Evstigneeva, "Synthesis of Carboranylporphyrins and the Perspectives of Their Use for Boron Neutron Capture Therapy," <i>Molecules</i> , 5: 1479-80 (2001).
20.		Zakharkin et al., "Synthesis of carboranyl derivatives of deuteroporphyrin IX," <i>Russian Chemical Bulletin</i> , 48(12): 2312-14 (1999).
21.		"Brain Tumor Patients Offered New Hope with Expanded Trial of Promising Therapy," Press Release, Brookhaven National Labs, Nov. 1998, < http://virtualtrials.com/bnct2.cfm >.
22.		Yarris, "Accelerator for Boron Neutron Capture Therapy Proposed by Lab," Jun. 21, 1996, Lawrence Berkeley National Laboratory, < http://www.lbl.gov/Science-Articles/Archive/boron-capture.html >.

EXAMINER

DATE CONSIDERED

11/9/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. BSA 04-02	SERIAL NO. Unassigned
	APPLICANT Haitao Wu et al.	CONFIRMATION NO. Unassigned
	FILING DATE Concurrently	GROUP Unassigned

WF	23.	Gomez, "Boron Neutron Capture Therapy (BNCT)," Dec. 1, 1998, Lawrence Berkeley National Laboratory, <http://www.virtualtrials.com/bnct.cfm>
	24.	Chu et al., Overview - LBNL/UCSF Boron Neutron Capture Proposal, <http://ehs.lbl.gov/bnct/overview.html>
	25.	Chu et al., Work in Progress - LBNL/UCSF Boron Neutron Capture Proposal, "Progress Report (4/97) on 'Accelerator-Based BNCT Clinical Trial'," < http://ehs.lbl.gov/bnct/progress.html >.
	26.	Ludewigt et al., "Research Topics and Papers, Neutron Production Target for the BNCT Project at Lawrence Berkeley National Laboratory and at the University of California at San Francisco, Project 2b - Neutron Production Target," < http://ehs.lbl.gov/bnct/research/target.html >.
	27.	Larson et al., "Research Topics and Papers, Phase I Study Concept for the BNCT Project at Lawrence Berkeley National Laboratory and at the University of California at San Francisco, Project 11 - Proposed BNCT Clinical Trials," < http://ehs.lbl.gov/bnct/research/proposedtrials.html >.
	28.	Deen et al, "Research Topics and Papers, Small Animal and <i>In Vitro</i> Toxicity and Biodistribution for the BNCT Project at Lawrence Berkeley National Laboratory and at the University of California at San Francisco, Project 6- Small Animal and <i>In Vitro</i> Toxicity, Biodistribution and Radiobiology," http://ehs.lbl.gov/bnct/research/smallanimal.html >.
	29.	Fike et al, "Research Topics and Papers, Small Animal and <i>In Vitro</i> Toxicity and Biodistribution for the BNCT Project at Lawrence Berkeley National Laboratory and at the University of California at San Francisco, Project 7- Large Animal Pharmacology and Toxicology," http://ehs.lbl.gov/bnct/research/largeanimal.html >.

EXAMINER

DATE CONSIDERED

11/9/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.